3,5-Disubstituted isoxazole derivatives: Potential inhibitors of inflammation and cancer

Rakesh, K. S. and Jagadish, S. and Balaji, K. S. and Zameer, F. and Swaroop, T. R. and Mohan, C. D. and Jayarama, S. and Rangappa, K. S. (2016) 3,5-Disubstituted isoxazole derivatives: Potential inhibitors of inflammation and cancer. Inflammation, 39 (1). pp. 269-281. ISSN 1573-2576

Text (Full Text) 3,5-Disubstituted Isoxazole Derivatives.pdf - Published Version Restricted to Registered users only Download (3MB) | Request a copy

Abstract

The products of arachidonic acid metabolism by lipoxygenase (LOX) and cyclooxygenase (COX) significantly contribute to inflammation and carcinogenesis. Particularly, overproduction of leukotrienes and prostaglandins contribute to tumor growth by inducing formation of new blood vessels that sustain tumor cell viability and growth. Hence, search for novel anticancer drug via inhibition of LOX and COX enzymes constitutes an impressive strategy till date. In this context, a series of isoxazole derivatives were synthesized and screened for their anti-inflammatory activity via LOX and COX inhibition. Among these, 3-(3-methylthiophen-2-yl)-5-(3,4,5-trimethoxyphenyl)isoxazole (2b) showed significant inhibitory activity toward LOX and COX-2. Additionally, 2b showed a good inhibition of tumor growth, peritoneal angiogenesis, and ascite formation in Ehrlich ascites carcinoma (EAC) cell mouse model. Further, the in silico molecular studies also revealed that the compound 2b binds to the catalytic domain of LOX and COX-1 and COX-2 strongly with high atomic contact energy (ACE) score compared to standard drug. These initial pharmacological data support the fact that the compound 2b serves as the basis in developing anti-inflammatory and anticancer agents.

Item Type:	Article
Subjects:	C Chemical Science > Chemistry
Divisions:	Department of > Chemistry
Depositing User:	Manjula P Library Assistant
Date Deposited:	25 Jun 2019 05:48
Last Modified:	21 Jun 2022 05:59
URI:	http://eprints.uni-mysore.ac.in/id/eprint/3791

Actions (login required)

View Item